Tevogen Bio Seeks 100M Share Plan Increase and Written Consent Amendment — Massive Dilution and Control Shift on the Table

summarizeSummary

Tevogen Bio's preliminary proxy seeks approval to add 100 million shares to its equity plan — a 15.6x increase over the current outstanding share count — and to allow stockholder action by written consent, which would let the 57.8% controlling CEO approve matters without a meeting.

check_boxKey Events · Corporate Governance and Compliance · TVGN

• 100M Share Plan Increase Proposed

  Proposal 3 seeks to increase the 2024 Omnibus Incentive Plan share reserve by 100,000,000 shares, from 2,800,000 to 102,800,000 — a 15.6x multiple of the 6,416,540 shares currently outstanding. Only 240,563 shares remain available for grants.

• Written Consent Amendment Concentrates Control

  Proposal 4 would amend the Charter to permit stockholder action by written consent. CEO Ryan Saadi holds 57.8% of voting power, enabling him to unilaterally approve most matters without a shareholder meeting or minority input.

• Governance Committee Disbanded

  The proxy discloses that the compensation committee and nominating and corporate governance committee were disbanded in April 2025. Independent directors now handle executive compensation, but no independent committee oversees nominations.

• Annual Meeting Set for August 24, 2026

  Shareholders of record as of July 23, 2026 will vote on the two director nominees, auditor ratification, the plan amendment, and the written consent amendment at a virtual meeting.

auto_awesomeAnalysis · TVGN · Life Sciences

Shareholders are being asked to approve a 100-million-share increase to Tevogen Bio's equity incentive plan — a 15.6x expansion over the current 6.4 million shares outstanding. With only 240,563 shares left for grants, the company is effectively out of equity compensation capacity. The board argues the increase is essential for attracting talent and aligning incentives, but the sheer scale — authorizing shares equal to 15.6 times the current float — creates enormous potential dilution. Separately, the company proposes allowing stockholder action by written consent. Because CEO Ryan Saadi controls 57.8% of the vote, this would let him approve most matters without a meeting or minority shareholder input, concentrating governance power. The proxy also reveals that the board disbanded its compensation and nominating committees in April 2025, leaving independent directors to handle executive pay — a structure that, combined with the proposed changes, raises governance concerns. The annual meeting is set for August 24, 2026.